Notice: This company has been marked as potentially delisted and may not be actively trading. aTyr Pharma (LIFE) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipTrends Get the Latest News and Ratings for LIFE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for aTyr Pharma and its competitors. Enter your email to sign up for newsletter Sign Up LIFE Analyst Ratings Over TimeTypeCurrent Forecast11/23/23 to 11/22/241 Month Ago10/24/23 to 10/23/243 Months Ago8/25/23 to 8/24/241 Year Ago11/23/22 to 11/23/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy2 Buy rating(s)2 Buy rating(s)2 Buy rating(s)5 Buy rating(s)Hold0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)1 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$25.50$25.50$25.50$20.75Forecasted UpsideN/A1,242.11% Upside1,242.11% Upside1,673.50% UpsideConsensus RatingBuyBuyBuyModerate Buy BREAKING: NVDA loses $175 billion in 8 minutes (Ad)It's a wild week for the legendary chipmaker. Nvidia just beat earnings expectations across every metric, with annual revenue up nearly 100%. So why did the stock abruptly plunge following the earnings release – losing $175 billion in just 8 minutes?Things are about to get even stranger. LIFE Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History LIFE Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table aTyr Pharma Stock vs. The CompetitionTypeaTyr PharmaMedical CompaniesS&P 500Consensus Rating Score 3.00 2.80 2.50Consensus RatingBuyModerate BuyModerate BuyPredicted UpsideN/A26,704.62% Upside8.53% UpsideNews Sentiment RatingNeutral NewsSee Recent LIFE NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails5/14/2024HC Wainwright2 of 5 stars Reiterated RatingBuy ➝ Buy$35.00+1,911.48%3/15/2024Royal Bank of Canada4 of 5 stars Lower TargetOutperform ➝ Outperform$19.00 ➝ $16.00+712.18%7/20/2023Piper Sandler2 of 5 stars Boost TargetOverweight$13.00 ➝ $20.00+885.22%7/5/2023OppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeOutperform ➝ Market Perform3/6/2023Roth MkmSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingBuy$9.00+316.67%3/3/2023Roth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingK. RajaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuyAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 12:25 PM ET. LIFE Forecast - Frequently Asked Questions What is aTyr Pharma's forecast for 2025? According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for aTyr Pharma is $25.50, with a high forecast of $35.00 and a low forecast of $16.00. Should I buy or sell aTyr Pharma stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LIFE shares. Does aTyr Pharma's stock price have much upside? According to analysts, aTyr Pharma's stock has a predicted upside of ∞ based on their 12-month stock forecasts. Do Wall Street analysts like aTyr Pharma more than its competitors? Analysts like aTyr Pharma more than other "medical" companies. The consensus rating for aTyr Pharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LIFE compares to other companies. Stock Forecasts and Research Tools Related Companies Pacific Biosciences of California Stock Forecast PTC Therapeutics Stock Forecast Sarepta Therapeutics Stock Forecast Thermo Fisher Scientific Stock Forecast Agilent Technologies Stock Forecast Mettler-Toledo International Stock Forecast Waters Stock Forecast Illumina Stock Forecast Bio-Techne Stock Forecast Charles River Laboratories International Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter The Death Knell for U.S. Stocks (Ad)They are among the 31 billionaires dumping their stocks at a record pace. Fortune calls this phenomenon "The Great Cash Out." And it means YOUR so-called "safe stocks"could get cut in half.Today, you'll discover the sobering truth. This page (NASDAQ:LIFE) was last updated on 11/22/2024 by MarketBeat.com Staff From Our PartnersHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBREAKING: NVDA loses $175 billion in 8 minutesIt's a wild week for the legendary chipmaker. Nvidia just beat earnings expectations across every metric, w...Chaikin Analytics | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe #1 Bitcoin ETF For Monthly DividendsYou don't have to own any Bitcoin to collect BIG dividends from it... Now, thanks to this brand new Bitcoin...Investors Alley | Sponsored“Trump Trades” You’ve Got to MakeThese Stocks are the Best “Trump Trades” Free e-book reveals sectors – and stocks within them – likely to p...StockEarnings | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LIFE Stock Alerts